Last reviewed · How we verify
mifepristone vaginal tablets
At a glance
| Generic name | mifepristone vaginal tablets |
|---|---|
| Also known as | mifepristone |
| Sponsor | BioPro Medical Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion (NA)
- Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone (EARLY_PHASE1)
- Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage (PHASE3)
- 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E (PHASE4)
- Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mifepristone vaginal tablets CI brief — competitive landscape report
- mifepristone vaginal tablets updates RSS · CI watch RSS
- BioPro Medical Ltd portfolio CI